Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk.
Some health concerns are often not identified until late into clinical development of drugs, which can place participants and patients at significant risk. For example, the United States Food and Drug Administration (FDA) labeled the xanthine oxidase inhibitor febuxostat with a"boxed" warn...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0291330&type=printable |
| _version_ | 1797682738961055744 |
|---|---|
| author | Ryan E Feaver M Scott Bowers Banumathi K Cole Steve Hoang Mark J Lawson Justin Taylor Brian D LaMoreaux Lin Zhao Brad R Henke Brian A Johns Andrew C Nyborg Brian R Wamhoff Robert A Figler |
| author_facet | Ryan E Feaver M Scott Bowers Banumathi K Cole Steve Hoang Mark J Lawson Justin Taylor Brian D LaMoreaux Lin Zhao Brad R Henke Brian A Johns Andrew C Nyborg Brian R Wamhoff Robert A Figler |
| author_sort | Ryan E Feaver |
| collection | DOAJ |
| description | Some health concerns are often not identified until late into clinical development of drugs, which can place participants and patients at significant risk. For example, the United States Food and Drug Administration (FDA) labeled the xanthine oxidase inhibitor febuxostat with a"boxed" warning regarding an increased risk of cardiovascular death, and this safety risk was only identified during Phase 3b clinical trials after its approval. Thus, better preclinical assessment of drug efficacy and safety are needed to accurately evaluate candidate drug risk earlier in discovery and development. This study explored whether an in vitro vascular model incorporating human vascular cells and hemodynamics could be used to differentiate the potential cardiovascular risk associated with molecules that have similar on-target mechanisms of action. We compared the transcriptomic responses induced by febuxostat and other xanthine oxidase inhibitors to a database of 111 different compounds profiled in the human vascular model. Of the 111 compounds in the database, 107 are clinical-stage and 33 are FDA-labelled for increased cardiovascular risk. Febuxostat induces pathway-level regulation that has high similarity to the set of drugs FDA-labelled for increased cardiovascular risk. These results were replicated with a febuxostat analog, but not another structurally distinct xanthine oxidase inhibitor that does not confer cardiovascular risk. Together, these data suggest that the FDA warning for febuxostat stems from the chemical structure of the medication itself, rather than the target, xanthine oxidase. Importantly, these data indicate that cardiovascular risk can be evaluated in this in vitro human vascular model, which may facilitate understanding the drug candidate safety profile earlier in discovery and development. |
| first_indexed | 2024-03-12T00:05:12Z |
| format | Article |
| id | doaj.art-73653be581c742099685677071b70e9b |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-12T00:05:12Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-73653be581c742099685677071b70e9b2023-09-17T05:31:14ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01189e029133010.1371/journal.pone.0291330Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk.Ryan E FeaverM Scott BowersBanumathi K ColeSteve HoangMark J LawsonJustin TaylorBrian D LaMoreauxLin ZhaoBrad R HenkeBrian A JohnsAndrew C NyborgBrian R WamhoffRobert A FiglerSome health concerns are often not identified until late into clinical development of drugs, which can place participants and patients at significant risk. For example, the United States Food and Drug Administration (FDA) labeled the xanthine oxidase inhibitor febuxostat with a"boxed" warning regarding an increased risk of cardiovascular death, and this safety risk was only identified during Phase 3b clinical trials after its approval. Thus, better preclinical assessment of drug efficacy and safety are needed to accurately evaluate candidate drug risk earlier in discovery and development. This study explored whether an in vitro vascular model incorporating human vascular cells and hemodynamics could be used to differentiate the potential cardiovascular risk associated with molecules that have similar on-target mechanisms of action. We compared the transcriptomic responses induced by febuxostat and other xanthine oxidase inhibitors to a database of 111 different compounds profiled in the human vascular model. Of the 111 compounds in the database, 107 are clinical-stage and 33 are FDA-labelled for increased cardiovascular risk. Febuxostat induces pathway-level regulation that has high similarity to the set of drugs FDA-labelled for increased cardiovascular risk. These results were replicated with a febuxostat analog, but not another structurally distinct xanthine oxidase inhibitor that does not confer cardiovascular risk. Together, these data suggest that the FDA warning for febuxostat stems from the chemical structure of the medication itself, rather than the target, xanthine oxidase. Importantly, these data indicate that cardiovascular risk can be evaluated in this in vitro human vascular model, which may facilitate understanding the drug candidate safety profile earlier in discovery and development.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0291330&type=printable |
| spellingShingle | Ryan E Feaver M Scott Bowers Banumathi K Cole Steve Hoang Mark J Lawson Justin Taylor Brian D LaMoreaux Lin Zhao Brad R Henke Brian A Johns Andrew C Nyborg Brian R Wamhoff Robert A Figler Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk. PLoS ONE |
| title | Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk. |
| title_full | Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk. |
| title_fullStr | Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk. |
| title_full_unstemmed | Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk. |
| title_short | Human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk. |
| title_sort | human cardiovascular disease model predicts xanthine oxidase inhibitor cardiovascular risk |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0291330&type=printable |
| work_keys_str_mv | AT ryanefeaver humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT mscottbowers humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT banumathikcole humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT stevehoang humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT markjlawson humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT justintaylor humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT briandlamoreaux humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT linzhao humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT bradrhenke humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT brianajohns humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT andrewcnyborg humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT brianrwamhoff humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk AT robertafigler humancardiovasculardiseasemodelpredictsxanthineoxidaseinhibitorcardiovascularrisk |